http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107693796-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107693796-B |
| titleOfInvention | PEG (polyethylene glycol) site-directed modified asparaginase injection |
| abstract | The invention relates to an N-terminal site-specific modified polyethylene glycol asparaginase injection and a preparation method thereof. The injection mainly comprises N-terminal site-specific modified pegylated asparaginase, buffer salt, a protein stabilizer and water, wherein the protein stabilizer is sorbitol. The N-terminal site-specific modified pegylation asparaginase injection can effectively improve the stability of asparaginase, reduce adverse reactions in the medication process, prolong the medication period, and reduce the administration times and pain of patients caused by injection administration. |
| priorityDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 263.